Citigroup
MRNA icon

Citigroup’s Moderna MRNA Stock Holding History

Citigroup’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21M Sell
300,000
-310,000
-51% -$16M 0.01% 1148
2026
Q1 		$31M Sell
610,000
-112,000
-16% -$5.23M 0.01% 855
2025
Q4 		$21.3M Buy
722,000
+704,100
+3,934% +$19.1M 0.01% 1073
2025
Q3 		$462K Sell
17,900
-12,100
-40% -$338K ﹤0.01% 3617
2025
Q2 		$828K Sell
30,000
-250,000
-89% -$6.58M ﹤0.01% 3301
2025
Q1 		$7.94M Buy
280,000
+165,000
+143% +$5.86M ﹤0.01% 1532
2024
Q4 		$4.78M Buy
+115,000
New +$5.5M ﹤0.01% 2009
2024
Q2 		– Sell
-6,000
Closed -$639K – 5708
2024
Q1 		$639K Sell
6,000
-13,000
-68% -$1.31M ﹤0.01% 3397
2023
Q4 		$1.89M Hold
19,000
– – ﹤0.01% 2289
2023
Q3 		$1.96M Hold
19,000
– – ﹤0.01% 1997
2023
Q2 		$2.31M Sell
19,000
-172,400
-90% -$23M ﹤0.01% 2071
2023
Q1 		$29.4M Buy
191,400
+33,000
+21% +$5.44M 0.02% 628
2022
Q4 		$28.5M Buy
158,400
+97,400
+160% +$15.9M 0.02% 627
2022
Q3 		$7.21M Buy
61,000
+4,000
+7% +$607K 0.01% 1330
2022
Q2 		$8.14M Sell
57,000
-104,500
-65% -$14.9M 0.01% 1257
2022
Q1 		$27.8M Sell
161,500
-15,500
-9% -$2.61M 0.02% 763
2021
Q4 		$45M Buy
177,000
+98,200
+125% +$28.7M 0.02% 602
2021
Q3 		$30.3M Sell
78,800
-39,300
-33% -$14.5M 0.02% 766
2021
Q2 		$27.8M Sell
118,100
-34,900
-23% -$6.24M 0.02% 815
2021
Q1 		$20M Buy
153,000
+55,100
+56% +$7.98M 0.01% 955
2020
Q4 		$10.2M Buy
97,900
+62,300
+175% +$6.3M 0.01% 1535
2020
Q3 		$2.52M Buy
35,600
+23,200
+187% +$1.62M ﹤0.01% 2446
2020
Q2 		$796K Buy
+12,400
New +$679K ﹤0.01% 3795

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Citigroup's MRNA Position: Q2 2026 in Review

Citigroup increased its Moderna (MRNA) stake by 46% in Q2 2026, buying an estimated $35.5M and bringing the position to 2,165,414 shares worth $152M. The position accounts for 0.05% of the portfolio, ranked #326.

Citigroup first reported a position in MRNA in Q1 2019 and has held it in 30 quarters since. The position peaked at $280M in Q4 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Citigroup held 2,165,414 shares of Moderna worth $152M as of Q2 2026.
  • Citigroup bought 685,380 Moderna shares in Q2 2026, an estimated $35.5M.
  • Moderna made up 0.05% of Citigroup's portfolio in Q2 2026, its #326 holding.
  • Citigroup first reported a position in Moderna in Q1 2019 and has held it in 30 quarters since.
  • Citigroup's Moderna position peaked at $280M in Q4 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.